{"id":"NCT00946920","sponsor":"Ferring Pharmaceuticals","briefTitle":"A Trial of Degarelix in Patients With Prostate Cancer","officialTitle":"An Open-Label, Multi-Centre, Randomised, Parallel-Arm One-Year Trial, Comparing the Efficacy and Safety of Degarelix Three-Month Dosing Regimen With Goserelin Acetate in Patients With Prostate Cancer Requiring Androgen Deprivation Therapy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-06","primaryCompletion":"2011-03","completion":"2011-03","firstPosted":"2009-07-27","resultsPosted":"2014-06-02","lastUpdate":"2014-06-02"},"enrollment":859,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Prostate Cancer"],"interventions":[{"type":"DRUG","name":"Degarelix","otherNames":["Firmagon","FE200486"]},{"type":"DRUG","name":"Goserelin acetate","otherNames":["Zoladex"]}],"arms":[{"label":"Degarelix 240 mg/480 mg","type":"EXPERIMENTAL"},{"label":"Goserelin acetate","type":"ACTIVE_COMPARATOR"}],"summary":"A phase 3, open-label, parallel group, one year trial comparing the efficacy and safety of degarelix 3-month depot with the established therapy goserelin acetate 3-month implant in patients with prostate cancer.","primaryOutcome":{"measure":"Cumulative Probability of Testosterone at Castrate Level (â‰¤0.5 ng/mL) With Degarelix","timeFrame":"From Day 28 to Day 364","effectByArm":[{"arm":"Degarelix 240 mg/480 mg","deltaMin":90,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"MALE","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":8},"locations":{"siteCount":126,"countries":["United States","Belgium","Canada","Czechia","Finland","Germany","Hungary","Mexico","Netherlands","Poland","Romania","Russia","Ukraine","United Kingdom"]},"refs":{"pmids":["34350976"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":58,"n":565},"commonTop":["Hot flush","Injection site pain","Injection site erythema","Injection site nodule","Weight increased"]}}